American College of Clinical Pharmacy
      Search      Cart
         

ACCP Report - July 2020

Pharmacotherapy's Impact Factor Increases to 3.473!


Impact factors are published each year by Clarivate Analytics, which provides multiple products related to scientific research insights. Impact factors reflect a journal’s performance and status through a record of how often its articles are cited in other biomedical journals. Each year, publishers and editorial teams eagerly await the release of IF data. The data released June 29 ranked journals with respect to citations during 2019 of articles published in 2017–2018.

The June 29 data reflect that the IF for Pharmacotherapy has increased to 3.473. The increase from last year’s value of 3.045 maintains Pharmacotherapy’s IF over an important threshold of 3.0 and reaches an all-time high. In addition, this increase can be placed in yet another perspective by understanding how Pharmacotherapy is ranked within its designated journal category, Pharmacy and Pharmacology. Last year, Pharmacotherapy ranked 97th out of 267 journals. This year, Pharmacotherapy improved to a ranking of 83rd out of 270 journals.

Although IF should not be the sole measure of journal quality, it remains a vital measure in biomedical publishing of a journal’s impact on its field. A journal’s citation metrics alongside data on downloads, international readership, and comparisons with other journals are all measures of its success.

Publication of Pharmacotherapy is made possible through the combined effort of many individuals, including publication staff, editors, editorial board members, and reviewers. Most important are the authors who choose to submit their best work to the journal.

The top 10 articles published in 2017–2018 with the most citations in 2019 are as follows:

  1. Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL. Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort.
  2. Luepke KH, Suda KJ, Boucher H, et al. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
  3. Burke KR, Schumacher CA, Harpe SE. SGLT 2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
  4. Stanton BE, Barasch NS, Tellor KB. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.
  5. Osusu Obeng A, Hamadeh I, Smith M. Review of Opioid Pharmacogenetics and Considerations for Pain Management.
  6. Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017.
  7. Reinig AM, Mirzaei S, Berlau DJ. Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies.
  8. Manzoor BS, Lee TA, Sharp LK, Walton SM, Gallanger WL, Nutescu EA. Real-world Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.
  9. Richards JR, Gordon BK, Danielson AR, Moulin AK. Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review.
  10. Veve MP, Wagner JL. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.